Summary of Study ST001205
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000809. The data can be accessed directly via it's Project DOI: 10.21228/M83X38 This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
Study ID | ST001205 |
Study Title | Peroxide antimalarial treatment of K13-mutant and -wildtype P. falciparum parasites |
Study Summary | Red blood cells (RBCs) infected with trophozoite stage P. falciparum parasites (Cam3.IIR539T or Cam3.IIrev lines) at 4% parasitaemia and 2% haematocrit were treated with 100 nM of DHA, OZ277 or OZ439 for a duration of 1, 3 and 5 h, respectively. The K13-mutant artemisinin resistant parasite line used was Cam3.IIR539T. The K13-wildtype artemisinin sensitive parasite line used was Cam3.IIrev. The Samples treated with vehicle (DMSO) acted as the untreated control. |
Institute | Monash University |
Last Name | Giannangelo |
First Name | Carlo |
Address | 381 Royal Parade, Parkville, Victoria, 3052, Australia |
carlo.giannangelo@monash.edu | |
Phone | 99039282 |
Submit Date | 2019-06-26 |
Raw Data Available | Yes |
Raw Data File Type(s) | raw(Thermo) |
Analysis Type Detail | LC-MS |
Release Date | 2019-07-17 |
Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Treatment:
Treatment ID: | TR001287 |
Treatment Summary: | RBCs infected with Cam3.IIR539T (resistant) or Cam3.IIrev (sensitive) P. falciparum parasites (22-26 h post invasion) at 4% parasitaemia and 2% Hct were treated with 100 nM of DHA, OZ277 or OZ439 (or an equivalent volume of DMSO) for 1, 3 and 5 h, respectively. During the drug incubation period parasite cultures were at 37°C under a gas atmosphere of 94% N2, 5% CO2 and 1% O2. |
Treatment Compound: | OZ277 (arterolane), OZ439 (artefenomel) and dihydroartemisinin (DHA) |
Treatment Vehicle: | DMSO |
Cell Media: | Complete RPMI medium (10.4 g/L) containing HEPES (5.94 g/L), hypoxanthine (50 mg/L), sodium bicarbonate (2.1 g/L) and Albumax II (5 g/L). |
Cell Media Lastchanged: | Immediately prior to initiation of drug incubation |